PubRank

P A Andrews

Author PubWeight™ 72.01‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA. J Natl Cancer Inst 1997 1.88
2 Endogenous complement C3 synthesis in immune complex nephritis. Lancet 1993 1.57
3 Reductive activation of mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome P-450 reductase and xanthine oxidase. J Biol Chem 1984 1.54
4 Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by glutathione depletion. Cancer Res 1985 1.30
5 Free proximal trisomy 21 without the Down syndrome. Clin Genet 1987 1.19
6 Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells. Int J Cancer 1991 1.18
7 Cancer incidence in the industrial corridor: an update. J La State Med Soc 1998 1.17
8 Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Cancer Res 1987 1.16
9 Skin tumours posttransplantation: a retrospective analysis of 28 years' experience at a single centre. Transplant Proc 1997 1.14
10 Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 1987 1.13
11 Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem 1990 1.10
12 Renal disease and use of topical non-steroidal anti-inflammatory drugs. BMJ 1994 1.10
13 Outcome of transplantation of non-heart-beating donor kidneys. Lancet 1995 1.09
14 Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 1996 1.05
15 Epidermal growth factor regulates the in vitro sensitivity of human ovarian carcinoma cells to cisplatin. J Clin Invest 1990 1.03
16 Short-term cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 1990 1.01
17 The adducted thumbs syndrome. An autosomal recessive disease with arthrogryposis, dysmyelination, craniostenosis, and cleft palate. Clin Genet 1971 0.97
18 Facile and definitive determination of human adriamycin and daunoribicin metabolites by high-pressure liquid chromatography. Drug Metab Dispos 1980 0.96
19 Hypermethylation of human DNA sequences in embryonal carcinoma cells and somatic tissues but not in sperm. Nucleic Acids Res 1987 0.96
20 Effect of intracellular chloride on the cellular pharmacodynamics of cis-diamminedichloroplatinum(II). Drug Metab Dispos 1995 0.91
21 Renal failure in a patient with chronic myelomonocytic leukaemia. Nephrol Dial Transplant 1997 0.91
22 Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 1998 0.91
23 High-dose cisplatin with sodium thiosulfate protection. J Clin Oncol 1985 0.90
24 Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 1991 0.89
25 Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. J Clin Oncol 1985 0.88
26 Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Anticancer Res 1989 0.88
27 Association between expression of glutathione-associated enzymes and response to platinum-based chemotherapy in head and neck cancer. Chem Biol Interact 1998 0.88
28 Safety and efficacy of TNFalpha blockade in relapsing vasculitis. Ann Rheum Dis 2002 0.87
29 NSAIDS in the postoperative period. Many factors threaten renal function. BMJ 1993 0.87
30 Predictive value of preclinical toxicology studies for platinum anticancer drugs. Clin Cancer Res 1999 0.87
31 Decreased cisplatin/DNA adduct formation is associated with cisplatin resistance in human head and neck cancer cell lines. Cancer Chemother Pharmacol 2000 0.86
32 Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett 1987 0.86
33 Modulation of cis-diamminedichloroplatinum (II) accumulation and cytotoxicity by spermine in sensitive and resistant human ovarian carcinoma cells. Eur J Cancer 1997 0.84
34 Differential sensitization of human ovarian carcinoma and mouse L1210 cells to cisplatin and melphalan by glutathione depletion. Mol Pharmacol 1986 0.83
35 Inhibitors of intracellular pH regulation induce cisplatin resistance in EMT6 mouse mammary tumor cells. Oncol Res 1995 0.82
36 Guidelines for liver transplantation for patients with non-alcoholic steatohepatitis. Gut 2012 0.82
37 Is there a 'cancer corridor' in Louisiana? J La State Med Soc 1996 0.81
38 Ring chromosome 12. Am J Med Genet 1988 0.80
39 The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells. Cancer Commun 1990 0.80
40 Cancer of the colon and rectum in Louisiana. J La State Med Soc 1999 0.80
41 Racial variation in dosage requirements of tacrolimus. Lancet 1996 0.80
42 Poorer graft survival in ethnic minorities: results from a multi-centre UK study of kidney transplant outcomes. Clin Nephrol 2011 0.80
43 Nocturnal body temperature regulation in man: a rationale for sweating in sleep. J Appl Physiol 1966 0.79
44 Glutathione content but not gamma glutamyl cysteine synthetase mRNA expression predicts cisplatin resistance in head and neck cancer cell lines. Cancer Chemother Pharmacol 1997 0.79
45 Rapid determination of C-reactive protein levels: semiquantitative versus quantitative. J Pediatr 1987 0.78
46 Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance. Cancer Res 1992 0.78
47 Kidney donation after paracetamol overdose. BMJ 1993 0.78
48 Pharmacokinetic study of intraperitoneal streptozotocin. Clin Invest Med 1992 0.78
49 Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol 1982 0.78
50 A regulatory view of the Medicines Act in the United Kingdom. J Clin Pharmacol 1984 0.78
51 Highlights of cancer incidence in Louisiana, 1988-1992. J La State Med Soc 1997 0.78
52 A high-performance liquid chromatographic assay with improved selectivity for cisplatin and active platinum (II) complexes in plasma ultrafiltrate. Anal Biochem 1984 0.78
53 Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells. Eur J Cancer 1990 0.78
54 Cellular pharmacologic strategies for overcoming drug resistance: potential applications to regional therapy. Eur J Surg Suppl 1991 0.77
55 Breast cancer: incidence, mortality, and early detection in Louisiana, 1988-1997. J La State Med Soc 2001 0.77
56 Cytomegalovirus infection and abdominal pain with mycophenolate mofetil: is there a link? Drug Saf 2001 0.77
57 Renal transplantation in a patient with loin pain hematuria syndrome. Clin Nephrol 2006 0.77
58 Drug accumulation and DNA platination in cells exposed to aquated cisplatin species. Cancer Lett 1994 0.77
59 Renal transplantation in Wiskott-Aldrich syndrome. Transplantation 1993 0.77
60 Disorders of iron metabolism. N Engl J Med 2000 0.77
61 Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells. Clin Cancer Res 1996 0.77
62 Preclinical and clinical experience with cisplatin resistance. Hematol Oncol Clin North Am 1995 0.76
63 Antiphospholipid syndrome and systemic lupus erythematosus. Lancet 1993 0.76
64 Increase in the ATP signal after treatment with cisplatin in two different cell lines studied by 31P NMR spectroscopy. Biochem Biophys Res Commun 1992 0.76
65 Lipoprotein glomerulopathy: a new cause of nephrotic syndrome after renal transplantation. Implications for renal transplantation. Nephrol Dial Transplant 1999 0.76
66 Ondansetron for symptomatic relief in terminal uraemia. Nephrol Dial Transplant 1995 0.76
67 Percutaneous endoscopic gastrostomy feeding. BMJ 1992 0.75
68 Successful pregnancy in cystinosis. JAMA 1994 0.75
69 Asymptomatic haematuria. Nephrological screening is important. BMJ 2000 0.75
70 Centoxin: the full story of its withdrawal. Br J Hosp Med 1993 0.75
71 Heart failure. Lancet 1998 0.75
72 The care of patients undergoing hemodialysis. N Engl J Med 1999 0.75
73 Not yet time for a paradigm shift away from angiotensin inhibitors in chronic kidney disease, but due diligence required. Int J Clin Pract 2010 0.75
74 Oversensitive dipsticks? A minimalist take on urinalysis for microscopic haematuria. Int J Clin Pract 2008 0.75
75 Diarrhoea as a side effect of digoxin. BMJ 1990 0.75
76 Considerations for toxicology studies of respiratory drug products. Regul Toxicol Pharmacol 1997 0.75
77 Cervical myxofibrosarcoma in a renal allograft recipient treated with murine anti-CD3 monoclonal antibody therapy. Nephrol Dial Transplant 1998 0.75
78 Palliative care for patients with terminal renal failure. Lancet 1995 0.75
79 Anti-glomerular basement membrane antibody-mediated nephritis: when not to treat. Nephrol Dial Transplant 1999 0.75
80 Immunosuppression in renal transplantation. This meta-analysis has little relevance to current practice. BMJ 1999 0.75
81 Risk of pneumonia after hospital treatment for pneumonia. Lancet 1992 0.75
82 Outcome of renal transplantation in Wiskott-Aldrich syndrome. Nephrol Dial Transplant 1998 0.75
83 Comparison of the pharmacokinetics of ultrafilterable cisplatin species detectable by derivatization with diethyldithiocarbamate or atomic absorption spectroscopy. Eur J Cancer 1990 0.75
84 Reversed-phase high-performance liquid chromatography analysis of 6-thioguanine applicable to pharmacologic studies in humans. J Chromatogr 1982 0.75
85 Rhesus immunization after renal transplantation. Transplantation 1996 0.75
86 Advanced stage at diagnosis: an explanation for higher than expected cancer death rates in Louisiana? J La State Med Soc 1994 0.75
87 Cellular resistance to platinating agents in ovarian carcinoma. Prog Clin Biol Res 1986 0.75
88 Qualitative analysis of trimethylsilylated daunosamine and N-alkylated analogs by gas chromatography--mass spectrometry. Anal Biochem 1982 0.75
89 Disposition and metabolism of adriamycin octanoylhydrazone (NSC 233853) in mice and rabbits. Drug Metab Dispos 1981 0.75
90 Intravascular haemolysis and interstitial nephritis in association with ciprofloxacin. Nephron 1999 0.75
91 Growth inhibition by thymidine of leukemic HL-60 and normal human myeloid progenitor cells. Cancer Res 1981 0.75
92 Evidence for increased synthesis of complement C4 in the renal epithelium of rats with passive Heymann nephritis. J Am Soc Nephrol 1997 0.75
93 Post-transplantation lymphoproliferative disorder: an unusual presentation in a patient receiving tacrolimus. Nephrol Dial Transplant 2000 0.75
94 Systemic and topical actions of leucocytic extracts on minute vessels of the bat wing. Bibl Anat 1967 0.75
95 Purification and characterization of aclacinomycin A and its metabolites from human urine. Drug Metab Dispos 1983 0.75
96 The pharmacology of intraperitoneally administered bleomycin. J Clin Oncol 1987 0.75
97 The effects of terbium on the cellular accumulation of cisplatin in MDA-MB-231 human breast tumor cells. Cancer Chemother Pharmacol 1997 0.75
98 Superoxide radical reactions with anthracycline antibiotics. Biochem Pharmacol 1985 0.75
99 The effects of terbium on the accumulation of cisplatin in human ovarian cancer cells. Biochim Biophys Acta 1995 0.75
100 Aviator's cancer. Lancet 1968 0.75
101 Disposition and metabolism of N,N-dimethyldaunorubicin and N,N-dimethyladriamycin in rabbits and mice. Drug Metab Dispos 1981 0.75
102 Louisiana Tumor Registry: new developments and activities. J La State Med Soc 1999 0.75